A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of JTT-861 Administered for 12 Weeks in Subjects with Heart Failure with Reduced Ejection Fraction

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JTT 861 (Primary)
Indications Chronic heart failure; Heart failure
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms POWER-HF
Sponsors Akros Pharma

Most Recent Events

13 Sep 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Sep 2025.
02 May 2024 Planned End Date changed from 1 Jun 2025 to 1 Sep 2025.
05 Sep 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight